Annual EBITDA
$106.60 M
+$81.56 M+325.73%
31 December 2023
Summary:
ANI Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently $106.60 million, with the most recent change of +$81.56 million (+325.73%) on 31 December 2023. During the last 3 years, it has risen by +$78.47 million (+278.99%). ANIP annual EBITDA is now at all-time high.ANIP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$13.42 M
-$30.48 M-178.63%
30 September 2024
Summary:
ANI Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$13.42 million, with the most recent change of -$30.48 million (-178.63%) on 30 September 2024. Over the past year, it has dropped by -$46.53 million (-140.52%). ANIP quarterly EBITDA is now -130.07% below its all-time high of $44.62 million, reached on 31 March 2024.ANIP Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$70.16 M
-$46.53 M-39.88%
30 September 2024
Summary:
ANI Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently $70.16 million, with the most recent change of -$46.53 million (-39.88%) on 30 September 2024. Over the past year, it has dropped by -$31.91 million (-31.27%). ANIP TTM EBITDA is now -44.61% below its all-time high of $126.66 million, reached on 31 March 2024.ANIP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ANIP EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +325.7% | -140.5% | -31.3% |
| 3 y3 years | +279.0% | -299.9% | +160.6% |
| 5 y5 years | +55.5% | -180.0% | -7.2% |
ANIP EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +3321.2% | -130.1% | at low | -44.6% | +566.5% |
| 5 y | 5 years | at high | +3321.2% | -130.1% | at low | -44.6% | +566.5% |
| alltime | all time | at high | +309.9% | -130.1% | +45.9% | -44.6% | +221.8% |
ANI Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$13.42 M(-178.6%) | $70.16 M(-39.9%) |
| June 2024 | - | $17.07 M(-61.8%) | $116.69 M(-7.9%) |
| Mar 2024 | - | $44.62 M(+103.9%) | $126.66 M(+18.8%) |
| Dec 2023 | $106.60 M(+325.7%) | $21.89 M(-33.9%) | $106.60 M(+4.4%) |
| Sept 2023 | - | $33.12 M(+22.5%) | $102.07 M(+28.6%) |
| June 2023 | - | $27.04 M(+10.1%) | $79.34 M(+46.0%) |
| Mar 2023 | - | $24.56 M(+41.6%) | $54.33 M(+117.0%) |
| Dec 2022 | $25.04 M(+703.6%) | $17.35 M(+67.0%) | $25.04 M(-596.9%) |
| Sept 2022 | - | $10.39 M(+413.2%) | -$5.04 M(-42.2%) |
| June 2022 | - | $2.02 M(-142.8%) | -$8.72 M(-42.0%) |
| Mar 2022 | - | -$4.73 M(-62.9%) | -$15.04 M(-582.6%) |
| Dec 2021 | $3.12 M(-88.9%) | -$12.73 M(-289.6%) | $3.12 M(-88.4%) |
| Sept 2021 | - | $6.71 M(-256.3%) | $26.92 M(-21.1%) |
| June 2021 | - | -$4.30 M(-132.0%) | $34.13 M(-10.7%) |
| Mar 2021 | - | $13.43 M(+21.3%) | $38.20 M(+35.8%) |
| Dec 2020 | $28.13 M(-53.7%) | $11.07 M(-20.5%) | $28.13 M(+28.8%) |
| Sept 2020 | - | $13.93 M(-6291.6%) | $21.84 M(-11.5%) |
| June 2020 | - | -$225.00 K(-106.7%) | $24.68 M(-43.5%) |
| Mar 2020 | - | $3.35 M(-29.9%) | $43.71 M(-28.0%) |
| Dec 2019 | $60.73 M(-11.4%) | $4.78 M(-71.5%) | $60.73 M(-19.7%) |
| Sept 2019 | - | $16.77 M(-10.9%) | $75.61 M(-2.5%) |
| June 2019 | - | $18.81 M(-7.7%) | $77.52 M(+4.4%) |
| Mar 2019 | - | $20.38 M(+3.7%) | $74.25 M(+8.3%) |
| Dec 2018 | $68.55 M(+21.7%) | $19.65 M(+5.2%) | $68.55 M(+8.3%) |
| Sept 2018 | - | $18.68 M(+20.2%) | $63.30 M(+3.5%) |
| June 2018 | - | $15.55 M(+6.0%) | $61.14 M(+2.5%) |
| Mar 2018 | - | $14.67 M(+1.9%) | $59.67 M(+6.0%) |
| Dec 2017 | $56.31 M(+33.0%) | $14.40 M(-12.9%) | $56.31 M(+15.0%) |
| Sept 2017 | - | $16.52 M(+17.4%) | $48.98 M(+5.7%) |
| June 2017 | - | $14.08 M(+24.4%) | $46.32 M(+6.8%) |
| Mar 2017 | - | $11.31 M(+60.1%) | $43.38 M(+2.4%) |
| Dec 2016 | $42.35 M(+6.8%) | $7.07 M(-49.0%) | $42.35 M(-3.0%) |
| Sept 2016 | - | $13.87 M(+24.5%) | $43.66 M(+8.4%) |
| June 2016 | - | $11.14 M(+8.4%) | $40.27 M(+3.4%) |
| Mar 2016 | - | $10.28 M(+22.6%) | $38.96 M(-1.7%) |
| Dec 2015 | $39.64 M(+64.9%) | $8.38 M(-20.0%) | $39.64 M(-8.8%) |
| Sept 2015 | - | $10.47 M(+6.5%) | $43.48 M(+2.6%) |
| June 2015 | - | $9.83 M(-10.3%) | $42.39 M(+37.6%) |
| Mar 2015 | - | $10.96 M(-10.3%) | $30.81 M(+28.0%) |
| Dec 2014 | $24.04 M(+1311.9%) | $12.21 M(+30.1%) | $24.07 M(+55.8%) |
| Sept 2014 | - | $9.39 M(-635.1%) | $15.45 M(+112.9%) |
| June 2014 | - | -$1.75 M(-141.5%) | $7.26 M(+34.8%) |
| Mar 2014 | - | $4.23 M(+17.7%) | $5.38 M(-695.7%) |
| Dec 2013 | $1.70 M(-106.3%) | $3.59 M(+201.3%) | -$903.60 K(-89.0%) |
| Sept 2013 | - | $1.19 M(-132.9%) | -$8.25 M(-47.1%) |
| June 2013 | - | -$3.63 M(+76.2%) | -$15.59 M(-18.8%) |
| Mar 2013 | - | -$2.06 M(-45.1%) | -$19.20 M(-29.5%) |
| Dec 2012 | -$27.23 M(-46.4%) | -$3.75 M(-39.0%) | -$27.25 M(-9.0%) |
| Sept 2012 | - | -$6.15 M(-15.0%) | -$29.95 M(-17.5%) |
| June 2012 | - | -$7.24 M(-28.4%) | -$36.33 M(-13.7%) |
| Mar 2012 | - | -$10.11 M(+56.7%) | -$42.11 M(-14.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | -$50.78 M(+12.0%) | -$6.45 M(-48.5%) | -$49.04 M(-14.9%) |
| Sept 2011 | - | -$12.53 M(-3.8%) | -$57.62 M(+2.4%) |
| June 2011 | - | -$13.02 M(-23.6%) | -$56.29 M(+5.3%) |
| Mar 2011 | - | -$17.04 M(+13.4%) | -$53.46 M(+17.9%) |
| Dec 2010 | -$45.34 M(+18.4%) | -$15.03 M(+34.2%) | -$45.34 M(-17.7%) |
| Sept 2010 | - | -$11.20 M(+9.8%) | -$55.11 M(+13.0%) |
| June 2010 | - | -$10.20 M(+14.4%) | -$48.78 M(+13.0%) |
| Mar 2010 | - | -$8.91 M(-64.1%) | -$43.17 M(+12.7%) |
| Dec 2009 | -$38.29 M(+113.1%) | -$24.80 M(+409.6%) | -$38.29 M(+149.6%) |
| Sept 2009 | - | -$4.87 M(+6.1%) | -$15.34 M(-10.6%) |
| June 2009 | - | -$4.59 M(+13.7%) | -$17.15 M(-5.1%) |
| Mar 2009 | - | -$4.03 M(+118.0%) | -$18.06 M(+0.4%) |
| Dec 2008 | -$17.97 M(+109.2%) | -$1.85 M(-72.3%) | -$17.99 M(-0.8%) |
| Sept 2008 | - | -$6.68 M(+21.4%) | -$18.14 M(+33.5%) |
| June 2008 | - | -$5.50 M(+39.0%) | -$13.59 M(+27.1%) |
| Mar 2008 | - | -$3.96 M(+97.6%) | -$10.69 M(+24.5%) |
| Dec 2007 | -$8.59 M(-341.5%) | -$2.00 M(-5.9%) | -$8.59 M(-354.7%) |
| Sept 2007 | - | -$2.13 M(-18.2%) | $3.37 M(-27.7%) |
| June 2007 | - | -$2.60 M(+40.2%) | $4.66 M(-6.7%) |
| Mar 2007 | - | -$1.86 M(-118.6%) | $5.00 M(+40.5%) |
| Dec 2006 | $3.56 M(-138.7%) | $9.96 M(-1290.2%) | $3.56 M(-143.5%) |
| Sept 2006 | - | -$836.80 K(-63.1%) | -$8.17 M(-11.8%) |
| June 2006 | - | -$2.27 M(-31.2%) | -$9.27 M(-4.0%) |
| Mar 2006 | - | -$3.30 M(+86.5%) | -$9.65 M(+4.9%) |
| Dec 2005 | -$9.20 M(-24.4%) | -$1.77 M(-8.5%) | -$9.20 M(-20.8%) |
| Sept 2005 | - | -$1.93 M(-27.3%) | -$11.62 M(-7.9%) |
| June 2005 | - | -$2.66 M(-6.5%) | -$12.61 M(+0.4%) |
| Mar 2005 | - | -$2.84 M(-32.0%) | -$12.56 M(+3.2%) |
| Dec 2004 | -$12.16 M(+104.3%) | -$4.18 M(+42.9%) | -$12.16 M(+25.3%) |
| Sept 2004 | - | -$2.93 M(+12.4%) | -$9.70 M(+18.5%) |
| June 2004 | - | -$2.60 M(+6.3%) | -$8.19 M(+13.9%) |
| Mar 2004 | - | -$2.45 M(+42.1%) | -$7.19 M(+20.6%) |
| Dec 2003 | -$5.95 M(+60.1%) | -$1.72 M(+21.7%) | -$5.96 M(+28.9%) |
| Sept 2003 | - | -$1.42 M(-11.7%) | -$4.63 M(+16.0%) |
| June 2003 | - | -$1.60 M(+31.4%) | -$3.99 M(+3.2%) |
| Mar 2003 | - | -$1.22 M(+214.8%) | -$3.87 M(+3.8%) |
| Dec 2002 | -$3.72 M(+39.0%) | -$387.90 K(-50.1%) | -$3.73 M(-21.7%) |
| Sept 2002 | - | -$777.80 K(-47.4%) | -$4.76 M(+29.6%) |
| June 2002 | - | -$1.48 M(+36.9%) | -$3.67 M(+21.7%) |
| Mar 2002 | - | -$1.08 M(-23.8%) | -$3.02 M(+14.9%) |
| Dec 2001 | -$2.68 M(-19.3%) | -$1.42 M(-560.6%) | -$2.62 M(+38.0%) |
| Sept 2001 | - | $307.80 K(-137.3%) | -$1.90 M(-33.6%) |
| June 2001 | - | -$825.40 K(+19.8%) | -$2.87 M(-16.9%) |
| Mar 2001 | - | -$689.00 K(-0.9%) | -$3.45 M(+6.0%) |
| Dec 2000 | -$3.31 M(+118.9%) | -$695.00 K(+6.0%) | -$3.25 M(+27.2%) |
| Sept 2000 | - | -$655.80 K(-53.5%) | -$2.56 M(+34.5%) |
| June 2000 | - | -$1.41 M(+186.4%) | -$1.90 M(+139.2%) |
| Mar 2000 | - | -$492.30 K(+62.5%) | -$795.30 K(+162.5%) |
| Dec 1999 | -$1.51 M(-39.9%) | - | - |
| June 1999 | - | -$303.00 K | -$303.00 K |
| Dec 1998 | -$2.52 M | - | - |
FAQ
- What is ANI Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for ANI Pharmaceuticals?
- What is ANI Pharmaceuticals annual EBITDA year-on-year change?
- What is ANI Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for ANI Pharmaceuticals?
- What is ANI Pharmaceuticals quarterly EBITDA year-on-year change?
- What is ANI Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for ANI Pharmaceuticals?
- What is ANI Pharmaceuticals TTM EBITDA year-on-year change?
What is ANI Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ANIP is $106.60 M
What is the all time high annual EBITDA for ANI Pharmaceuticals?
ANI Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $106.60 M
What is ANI Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, ANIP annual earnings before interest, taxes, depreciation & amortization has changed by +$81.56 M (+325.73%)
What is ANI Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ANIP is -$13.42 M
What is the all time high quarterly EBITDA for ANI Pharmaceuticals?
ANI Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $44.62 M
What is ANI Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, ANIP quarterly earnings before interest, taxes, depreciation & amortization has changed by -$46.53 M (-140.52%)
What is ANI Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ANIP is $70.16 M
What is the all time high TTM EBITDA for ANI Pharmaceuticals?
ANI Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $126.66 M
What is ANI Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, ANIP TTM earnings before interest, taxes, depreciation & amortization has changed by -$31.91 M (-31.27%)